-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and change rate from 2016 to Q2 2023.
- Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Jun 2023 was $2.24M, a 75.6% decline year-over-year.
- Nabriva Therapeutics plc Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 30 Jun 2023 was $29.6M, a 16.4% decline year-over-year.
- Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $36.9M, a 27.8% increase from 2021.
- Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $28.9M, a 475% increase from 2020.
- Nabriva Therapeutics plc annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $5.03M, a 47% decline from 2019.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)